Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbsp
    Powder for the preparation of solution for intravenous and intramuscular injection.
    Composition:
    Cefoperazone sodium in terms of cefoperazone - 0.5 g;

    Sulbactam sodium in terms of sulbactam - 0.5 g.
    Description:The powder is white or almost white.
    Pharmacotherapeutic group:Antibiotic-cephalosporin + beta-lactamase inhibitor.
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:

    The antibacterial component of cefoperazone + sulbactam is cefoperazone - a third generation cephalosporin antibiotic that acts on sensitive microorganisms during their active propagation by inhibiting the biosynthesis of the mucopeptide of the cell wall. Sulbactam does not have clinically significant antibacterial activity (except for Neisseriaceae and Acinetobacter), but is an irreversible inhibitor of most major beta-lactamases, which are produced by microorganism resistant to beta-lactam antibiotics. Sulbactam binds to some penicillin-binding proteins, as a result of which the combination of cefoperazone and sulbactam often exerts a more pronounced effect on sensitive strains than simply cefoperazone.

    The combination of cefoperazone with sulbactam is active against all microorganisms sensitive to cefoperazone. In addition, it has a synergistic effect on various microorganisms, primarily: Haemophilus influenzae, Bacteroides species, Staphylococcus species, Acinetobacter calcoaceticus, Enterobacter aerogenes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacterfreundii, Enterobacter cloacae, Citrobacter diversus.

    Cefoperazone + sulbactam is active in vitro for a wide range of the following clinically relevant microorganisms:

    Gram-positive microorganisms

    Staphylococcus aureus (producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic group streptococcus A), Streptococcus agalactiae (beta-hemolytic streptococcus group B), most other strains of beta-hemolytic streptococci, Streptococcus faecalis (enterococci).

    Gram-negative microorganisms

    Escherichia coli, Klebsiella species, Enterobacter species, Citrobacter species, Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia species, Serratia species (including Serratia marcescens), Salmonella species and Shigella species, Pseudomonas aeruginosa and some others Pseudomonas species, Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica.

    Anaerobic microorganisms

    Gram-negative sticks (including Bacteroides fragilis, others Bacteroides species and Fusobacterium species).

    Gram-positive and gram-negative cocci (including Peptococcus species, Peptostreptococcus species and Veillonella species).

    Gram-positive sticks (including Clostridium species, Eubacterium species and Lactobacillus species).

    Pharmacokinetics:

    Both sulbactam and cefoperazone well distributed into various tissues and fluids, including bile, gall bladder, skin, appendix, fallopian tubes, ovaries, uterus and others.

    The maximum concentrations of sulbactam and cefoperazone after intravenous administration of 2 g of cefoperazone + sulbactam (1 g of sulbactam, 1 g of cefoperazone) for 5 minutes averages 130.2 μg / ml and 236.8 μg / ml, respectively. This reflects a higher volume of distribution of sulbactam (Vd = 18.0-27.6 l) compared with that of cefoperazone (Vd = 10.2-11.3 L).

    Approximately 84% of sulbactam and 25% of cefoperazone are excreted by the kidneys. The rest of cefoperazone is excreted mainly with bile. With parenteral administration of the drug, the half-life of sulbactam averages about 1 hour, and cefoperazone - 1.7 hours. Serum concentration is proportional to the administered dose.

    With repeated application of significant changes in the pharmacokinetics of both components of cefoperazone + sulbactam is not noted.

    When the drug is administered every 8-12 hours, cumulation is not observed.

    Pharmacokinetics for violations of liver function

    Cefoperazone is actively excreted with bile. The half-life of cefoperazone usually lengthens, and the excretion of the drug by the kidneys increases in patients suffering from liver diseases and / or obstruction of the biliary tract.Even with severe violations of the liver in bile, the therapeutic concentration of cefoperazone is reached, and the elimination half-life is only 2-4 times.

    Pharmacokinetics in renal impairment

    In patients with varying degrees of impaired renal function receiving cefoperazone + sulbactam, a high correlation was found between the total clearance of sulbactam from the body and the estimated clearance of creatinine. In patients with terminal renal failure, a significant lengthening of the half-life of sulbactam (an average of 6.9 hours and 9.7 hours in various studies) was detected. Hemodialysis causes significant changes in the half-life, total clearance from the body and the volume of distribution of sulbactam.

    Pharmacokinetics in the elderly

    In elderly people with renal insufficiency and impaired liver function, an increase in the half-life period, a decrease in clearance and an increase in the volume of distribution of both sulbactam and cefoperazone are observed. The pharmacokinetics of sulbactam correlates with the degree of renal dysfunction, and the pharmacokinetics of cefoperazone - with the degree of impaired hepatic function.

    Pharmacokinetics in children

    Children have no significant differences in the pharmacokinetics of the components of cefoperazone + sulbactam compared with adults. The half-life of sulbactam in children varies from 0.91 to 1.42 h, and cefoperazone from 1.44 to 1.88 h.

    Indications:
    Cefoperazone + sulbactam is indicated for the treatment of the following infections caused by susceptible microorganisms:

    infections of the upper and lower respiratory tract;

    urinary tract infections;

    peritonitis, cholecystitis, cholangitis and other intra-abdominal infections;

    sepsis;

    meningitis;

    infections of the skin and soft tissues;

    infection of bones and joints;

    inflammatory diseases of the pelvic organs, endometritis, gonorrhea and other infections of the genito-urinary tract.
    Contraindications:Cefoperazone + sulbactam is contraindicated in patients with allergies to penicillins, sulbactam, cefoperazone or any other beta-lactam antibiotics.
    Carefully:Patients with severe impairment of liver and kidney function; with colitis (including history); in premature newborns.
    Pregnancy and lactation:
    In pregnancy, the drug is used only if the expected benefit to the mother exceeds the potential risk to the fetus.
    In the case of taking the drug during lactation, breastfeeding should be discontinued.
    Dosing and Administration:

    Intravenous and intramuscular.

    Application in adults

    In adults cefoperazone + sulbactam it is recommended to use in the following daily doses:

    Ratio Cefoperazone + Sulbactam (d) Sulbactam, Cefoperazone,

    dose (g) dose (g)

    1 : 1 2,0-4,0 1,0-2,0 1,0-2,0

    The daily dose should be divided into equal parts and administered every 12 hours.

    In severe or refractory infections, the daily dose of cefoperazone + sulfate can be increased to 8 g (with a 1: 1 ratio of the major components, i.e. 4 g of cefoperazone and 4 g of sulbactam). If you need more than 8 g (with a 1: 1 ratio of the main components), an increase in the dose is achieved by the additional administration of cefoperazone. The dose should be divided into equal parts and administered every 12 hours.

    The recommended maximum daily dose of sulbactam is 4 g.

    Application for renal dysfunction

    Patients with a creatinine clearance of 15-30 ml / min should receive a maximum of 1 g of sulbactam every 12 hours (maximum daily dose of sulbactam is 2 g), patients with creatinine clearance less than 15 ml / min - maximum 500 mg of sulbactam every 12 hours (maximum daily dose sulbactam - 1 g).In severe infections, additional administration of cefoperazone may be required.

    The pharmacokinetics of sulbactam significantly changes during hemodialysis. The half-life of cefoperazone from the blood serum decreases slightly during hemodialysis. In this regard, the administration of the drug should be carried out after dialysis.

    In patients with impaired hepatic function and concomitant renal dysfunction, if regular monitoring of serum concentration of cefoperazone is not performed, the maximum daily dose should not exceed 2 g (see section "Special instructions").

    Application the children

    Children cefoperazone + sulbactam it is recommended to use in the following daily doses:

    Ratio Cefoperazone + Sulbactam Sulbactam, Cefoperazone,

    (mg / kg / day) dose (mg / kg / day) dose (mg / kg / day)

    1:1 40-80 20-40 20-40

    Dozu should be divided into equal parts and administered every 6-12 hours.

    In severe or refractory infections, the daily dose of cefoperazone + sulbactam can be increased to 160 mg / kg / day (with a 1: 1 ratio of the major components, ie 80 mg / kg / day of cefoperazone and 80 mg / kg / day of sulbactam). If it is necessary to administer more than 160 mg / kg / day (with a 1: 1 ratio of the main components), an increase in dose is achieved by the additional administration of cefoperazone.The dose should be divided into equal parts and administered every 6-12 hours.

    Application the newborns

    In newborns during the first week of life, the drug should be injected every 12 hours.

    The maximum daily dose of sulbactam in children should not exceed 80 mg / kg / day.

    Method of preparing solutions for parenteral use

    Preparation of the solution

    Total dose (g)

    Equivalent doses

    Scope

    Max, the final

    cefoperazone + sulbactam (g)

    solute

    conc. (mg / ml)

    bodies

    1,0

    0,5 + 0,5

    3,4

    125 + 125

    Intramuscular injection

    To prepare the solution for intramuscular injection, water for injection can be used (see table above).

    For the convenience of administration, it is also possible to prepare a solution of the preparation with a concentration of cefoperazone 250 mg / ml or more. In this case, the solution is prepared in two steps, using water for injection as solvents first, and then 2% solution of lidocaine hydrochloride (see below), since for initial dissolution lidocaine hydrochloride solution can not be directly applied.

    Preparation of a solution using lidocaine. Initially, the powder is dissolved in 1.3 ml of sterile water for injection, and then 0.4 ml of a 2% solution of lidocaine hydrochloride is added. The total volume of the solvent is 1.7 ml.The final solution will contain in 1 ml of a 0.5% solution of lidocaine hydrochloride about 250 mg of cefoperazone and about 250 mg of sulbactam.

    Intravenous administration

    To prepare a solution for infusion of 1 g (0.5 g + 0.5 g) of cefoperazone + sulbactam dissolved in the initial volume (approximately 3.4 ml) of one of the following infusion solutions: 5% glucose solution (dextrose), 5% glucose solution in physiological solution, 5% glucose solution in 0.225% sodium chloride solution, 0.9% sodium chloride solution or sterile water for injections, and then diluted to 20 ml with the same solution.

    Preparation of the solution using Ringer's lactate. Since Ringer's lactate is not suitable for initial dilution, the solution is prepared in two steps: first use sterile water for injection (see table above), and then dilute the resulting solution with Ringer's lactate solution to a 5 mg / ml sulbactam concentration (2 ml of the initial solution diluted in 50 ml of Ringer's lactate solution or 4 ml in 100 ml of Ringer's lactate solution).

    Infusion is carried out for 15-60 minutes.

    For intravenous injection the contents of each vial should be dissolved in 3.4 ml of one of the solvents described in the preparation of the infusion solution (see above) and administered for a minimum of 3 minutes.

    Side effects:

    The drug is usually well tolerated. The following reactions were noted:

    The cardiovascular system: lowering of blood pressure.

    Gastrointestinal tract: diarrhea, nausea, vomiting, pseudomembranous colitis.

    Allergic reactions: maculopapular rash, hives, as well as itching, Stevens-Johnson syndrome, anaphylactic shock. The risk of reactions is higher in patients with allergic reactions in the anamnesis.

    The system of hematopoiesis: decrease in the number of neutrophils; with long-term treatment - reversible neutropenia, decreased hemoglobin and hematocrit, transient eosinophilia, thrombocytopenia, leukopenia, hypoprothrombinemia, bleeding (due to vitamin K deficiency).

    Local reactions: the drug is well tolerated by intramuscular injection. Sometimes, after intramuscular injection, there is transient pain and burning at the injection site. With intravenous administration through the catheter, phlebitis can develop at the site of administration.

    Laboratory indicators: transient increase in "hepatic" transaminases - aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and bilirubin in blood serum, hematuria, hypercreatininaemia.In some patients, a false positive Coombs test was observed during treatment. When using a solution of Benedict or Felling, a false positive reaction to glucose in the urine can be observed.

    Others: headache, fever, chills, vasculitis.

    Overdose:
    Symptoms: neurological disorders, including convulsions.

    Treatment: symptomatic.

    In the case of an overdose in patients with impaired renal function, the removal of the drug from the body can be facilitated by hemodialysis.
    Interaction:

    Aminoglycosides

    Solutions cefoperazona + sulbactam and aminoglycosides should not be mixed, given the pharmaceutical incompatibility between them. If combined therapy with cefoperazone + sulbactam and aminoglycoside is used, the two drugs are administered by successive infusions using separate secondary catheters, and the primary catheter is washed between doses of the drugs. The intervals between the administration of cefoperazone + sulbactam and aminoglycoside during the day should be as much as possible.

    Alcohol

    When taking alcohol during treatment with cefoperazone and within 5 days after its administration, reactions were recorded,characterized by hot flashes, sweating, headache and tachycardia, so patients should be warned about the possibility of their appearance when drinking alcoholic beverages on the background of treatment with cefoperazonom + sulbactam. Patients who need artificial feeding (inside or parenteral) should avoid using solutions containing ethanol.

    Ringer's solution, 2% lidocaine hydrochloride solution

    The solution of cefoperazone + sulbactam is incompatible with Ringer's solution and 2% solution of lidocaine hydrochloride by direct mixing. Compatibility is achieved as a result of two-stage preparation: initially cefoperazone + sulbactam dissolve in water for injection, and then add Ringer's solution or 2% lidocaine hydrochloride solution.

    Special instructions:
    Patients who received beta-lactam antibiotics, including cephalosporins, described cases of hypersensitivity reactions, the risk of which is higher in patients who have a history of hypersensitivity reactions. In case of an allergic reaction, it is necessary to cancel the drug and prescribe the appropriate therapy.
    Anaphylactic reactions require the immediate administration of epinephrine. According to the indications, oxygen, intravenously injected glucocorticosteroids and provide airway patency, including intubation.
    A dose change may be required in cases of severe obstruction of the biliary tract, severe impairment of liver function, and impaired renal function associated with any of these conditions.
    In patients with impaired liver function and concomitant renal dysfunction, monitoring the serum concentration of cefoperazone and correcting its dose should be necessary.
    In the treatment of cefoperazone, like other antibiotics, in rare cases, it is developing a deficiency of vitamin C. The reason for it is probably the suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, suffering from malabsorption (for example, in cystic fibrosis) and for a long time on intravenous artificial feeding. In such cases, as well as in patients receiving anticoagulants, it is necessary to monitor prothrombin time and, in the presence of indications, prescribe vitamin K.
    With prolonged treatment with cefoperazonom + sulbactam, as with other antibiotics, excessive growth of insensitive microorganisms can be observed. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system. This is especially important for newborns, especially premature babies, and small children.
    When used simultaneously with aminoglycosides, it is necessary to monitor kidney function.
    Form release / dosage:Powder for solution for intravenous and intramuscular injection 0.5 g + 0.5 g.
    Packaging:1 g of the sum of active substances (0.5 g + 0.5 g) in a glass bottle sealed with a rubber stopper, rolled up with an aluminum cap with a plastic lid. 1 bottle with instructions for use or 50 bottles along with 3-5 instructions for use in a cardboard box.
    Storage conditions:
    Store in a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children. List B.

    Shelf life:
    2 years. Do not use after the expiry date printed on the package.
    The prepared injection solution is suitable for use for 18 hours at a temperature of no higher than 25 ° C.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-005034/07
    Date of registration:21.12.2007
    The owner of the registration certificate:Orchid Helsker (a division of Orchid Chemicals and Pharmaceuticals Ltd.)Orchid Helsker (a division of Orchid Chemicals and Pharmaceuticals Ltd.) India
    Manufacturer: & nbsp
    Representation: & nbspOrchid Chemicals and Pharmaceuticals Co., Ltd.Orchid Chemicals and Pharmaceuticals Co., Ltd.Russia
    Information update date: & nbsp26.10.2015
    Illustrated instructions
      Instructions
      Up